Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes

R. A. De Fronzo, C. F. Burant, P. Fleck, C. Wilson, Q. Mekki, R. E. Pratley

Research output: Contribution to journalArticlepeer-review

80 Scopus citations

Abstract

Context: Optimal management of type 2 diabetes remains an elusive goal. Combination therapy addressing the core defects of impaired insulin secretion and insulin resistance shows promise in maintaining glycemic control. Objective: The aim of the study was to assess the efficacy and tolerability of alogliptin combined with pioglitazone in metformin-treated type 2 diabetic patients. Design, Setting, and Patients: We conducted a multicenter, randomized, double-blind, placebocontrolled, parallel-arm study in patients with type 2 diabetes. Interventions: The study consisted of 26-wk treatment with alogliptin (12.5 or 25 mg qd) alone or combined with pioglitazone (15, 30, or 45 mg qd) in 1554 patients on stable-dose metformin monotherapy (>1500 mg) with inadequate glycemic control. Main Outcome Measure: The primary endpoint was change in glycosylated hemoglobin (HbA1c) from baseline to wk 26. Secondary endpoints included changes in fasting plasma glucose and β-cell function. Primary analyses compared pioglitazone therapy [all doses pooled, pioglitazone alone (Pio alone); n = 387] with alogliptin 12.5 mg plus any dose of pioglitazone (A12.5 + P; n = 390) or alogliptin 25 mg plus any dose of pioglitazone (A25 + P; n = 390). Results: When added to metformin, the least squares mean change (LSMA) from baseline HbA1c was -0.9 ± 0.05% in the Pio-alone group and -1.4 ± 0.05% in both the A12.5 + P and A25 + P groups (P < 0.001 for both comparisons). A12.5 + P and A25 + P produced greater reductions in fasting plasma glucose (LSMA = -2.5 ± 0.1 mmol/liter for both) than Pio alone (LSMA = -1.6 ± 0.1 mmol/liter; P < 0.001). A12.5 + P and A25 + P significantly improved measures of β-cell function (proinsulin:insulin and homeostasis model assessment of β-cell function) compared to Pio alone, but had no effect on homeostasis model assessment of insulin resistance. The LSMA body weight was 1.8 ± 0.2, 1.9 ± 0.2, and 1.5 ± 0.2 kg in A12.5 + P, A25 + P, and Pio-alone groups, respectively. Hypoglycemia was reported by 1.0,1.5, and 2.1% of patients in the A12.5 + P, A25 + P, and Pio-alone groups, respectively. Conclusions: In type 2 diabetic patients inadequately controlled by metformin, the reduction in HbA1c by alogliptin and pioglitazone was additive. The decreases in HbA1c with A12.5 +P and A25 + P were similar. All treatments were well tolerated.

Original languageEnglish (US)
Pages (from-to)1615-1622
Number of pages8
JournalJournal of Clinical Endocrinology and Metabolism
Volume97
Issue number5
DOIs
StatePublished - May 2012

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Fingerprint Dive into the research topics of 'Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes'. Together they form a unique fingerprint.

Cite this